by support | Nov 28, 2022 | Uncategorized
by Amy Leitman At the end of June I attended DIA 2016, the annual conference for the Drug Information Association, as part of their Patient Advocacy Fellowship Program. The Fellowship Program is a major initiative designed to build industry awareness of the...
by support | Nov 28, 2022 | Uncategorized
Aradigm, the company that submitted Linhaliq to the FDA for approval, announced that they had received a complete response letter (CRL) from the FDA stating that they would not approve the treatment at this time. Many of you have communicated recently with the FDA...
by support | Nov 28, 2022 | Uncategorized
NTM Info & Research and the COPD Foundation is happy to announce the release of the Bronchiectasis and NTM Information Line: 1-833-411-LUNG (5864). The Bronchiectasis and NTM Information Line is a toll-free number managed by the C.O.P.D. Information Line for...
by support | Nov 28, 2022 | Uncategorized
The Food and Drug Administration is convening a public workshop titled “Development of Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis” on Wednesday, June 27th from 8:30pm to 4:30pm ET. The purpose of this workshop is...
by support | Nov 28, 2022 | Uncategorized
Our continuing education-accredited conference is a groundbreaking opportunity for health care providers, researchers, patients, families, and caregivers to learn about the latest advances in research, treatment, and care from leaders in the field of nontuberculous...
by support | Nov 28, 2022 | Uncategorized
ARIKAYCE® is currently the only FDA approved drug designed specifically for NTM (MAC) and now available through prescription from your physician for treatment of refractory MAC lung infection in adult patients. This medication is only available through select...